Compare Cadila Healthcare with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CADILA HEALTHCARE vs ASTRAZENECA PHARMA - Comparison Results

CADILA HEALTHCARE     Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CADILA HEALTHCARE ASTRAZENECA PHARMA CADILA HEALTHCARE/
ASTRAZENECA PHARMA
 
P/E (TTM) x 14.0 78.5 17.9% View Chart
P/BV x 2.7 22.1 12.4% View Chart
Dividend Yield % 1.5 0.0 -  

Financials

 CADILA HEALTHCARE   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    CADILA HEALTHCARE
Mar-18
ASTRAZENECA PHARMA
Mar-18
CADILA HEALTHCARE/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs5581,278 43.7%   
Low Rs362883 41.0%   
Sales per share (Unadj.) Rs116.3228.4 50.9%  
Earnings per share (Unadj.) Rs17.910.4 172.4%  
Cash flow per share (Unadj.) Rs23.116.3 142.3%  
Dividends per share (Unadj.) Rs3.500-  
Dividend yield (eoy) %0.80-  
Book value per share (Unadj.) Rs85.498.8 86.5%  
Shares outstanding (eoy) m1,023.7425.00 4,095.0%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.04.7 83.6%   
Avg P/E ratio x25.7104.2 24.7%  
P/CF ratio (eoy) x19.966.4 29.9%  
Price / Book Value ratio x5.410.9 49.2%  
Dividend payout %19.60-   
Avg Mkt Cap Rs m470,66427,008 1,742.7%   
No. of employees `00011.81.4 871.6%   
Total wages/salary Rs m18,5451,535 1,207.9%   
Avg. sales/employee Rs Th10,072.74,210.9 239.2%   
Avg. wages/employee Rs Th1,569.11,132.2 138.6%   
Avg. net profit/employee Rs Th1,547.7191.1 810.0%   
INCOME DATA
Net Sales Rs m119,0495,710 2,084.9%  
Other income Rs m1,132123 924.1%   
Total revenues Rs m120,1815,833 2,060.5%   
Gross profit Rs m28,475463 6,151.4%  
Depreciation Rs m5,388147 3,655.4%   
Interest Rs m9110-   
Profit before tax Rs m23,308438 5,321.5%   
Minority Interest Rs m6280-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m5,644179 3,154.8%   
Profit after tax Rs m18,292259 7,059.8%  
Gross profit margin %23.98.1 295.0%  
Effective tax rate %24.240.8 59.3%   
Net profit margin %15.44.5 338.6%  
BALANCE SHEET DATA
Current assets Rs m82,0053,209 2,555.3%   
Current liabilities Rs m60,7202,070 2,934.0%   
Net working cap to sales %17.920.0 89.6%  
Current ratio x1.41.6 87.1%  
Inventory Days Days7372 101.1%  
Debtors Days Days9835 281.5%  
Net fixed assets Rs m83,703790 10,591.3%   
Share capital Rs m1,02450 2,048.0%   
"Free" reserves Rs m86,4212,419 3,572.1%   
Net worth Rs m87,4452,469 3,541.3%   
Long term debt Rs m25,5510-   
Total assets Rs m180,6534,605 3,922.6%  
Interest coverage x26.6NM-  
Debt to equity ratio x0.30-  
Sales to assets ratio x0.71.2 53.2%   
Return on assets %10.65.6 188.9%  
Return on equity %20.910.5 199.4%  
Return on capital %22.017.7 124.0%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m42,683300 14,249.0%   
Fx outflow Rs m11,2422,015 557.9%   
Net fx Rs m31,441-1,715 -1,832.9%   
CASH FLOW
From Operations Rs m9,19388 10,458.5%  
From Investments Rs m-9,737-94 10,402.8%  
From Financial Activity Rs m515NA-  
Net Cashflow Rs m-29-6 508.8%  

Share Holding

Indian Promoters % 74.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 8.3 0.3 2,766.7%  
FIIs % 5.9 15.7 37.6%  
ADR/GDR % 0.0 0.0 -  
Free float % 11.0 9.1 120.9%  
Shareholders   44,069 12,856 342.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CADILA HEALTHCARE With:   ALKEM LABORATORIES  FRESENIUS KABI ONCO.  FDC LTD.  TORRENT PHARMA  PLETHICO PHARMA  

Compare CADILA HEALTHCARE With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Extend Gains; Tata Motors & ONGC Climb 5%(12:30 pm)

Share markets in India have extended early morning gains and are presently trading higher. Investors are cautious ahead of the release of Consumer Price Index-based inflation.

Related Views on News

CADILA HEALTHCARE Announces Quarterly Results (1QFY20); Net Profit Down 28.9% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, CADILA HEALTHCARE has posted a net profit of Rs 3 bn (down 28.9% YoY). Sales on the other hand came in at Rs 35 bn (up 20.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 236.5% (Quarterly Result Update)

Aug 8, 2019 | Updated on Aug 8, 2019

For the quarter ended June 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 215 m (up 236.5% YoY). Sales on the other hand came in at Rs 2 bn (up 26.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

CADILA HEALTHCARE Announces Quarterly Results (4QFY19); Net Profit Down 21.0% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, CADILA HEALTHCARE has posted a net profit of Rs 5 bn (down 21.0% YoY). Sales on the other hand came in at Rs 37 bn (up 14.8% YoY). Read on for a complete analysis of CADILA HEALTHCARE's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (4QFY19); Net Profit Up 204.9% (Quarterly Result Update)

May 27, 2019 | Updated on May 27, 2019

For the quarter ended March 2019, ASTRAZENECA PHARMA has posted a net profit of Rs 98 m (up 204.9% YoY). Sales on the other hand came in at Rs 2 bn (up 26.3% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

ASTRAZENECA PHARMA 2017-18 Annual Report Analysis (Annual Result Update)

Mar 29, 2019 | Updated on Mar 29, 2019

Here's an analysis of the annual report of ASTRAZENECA PHARMA for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of ASTRAZENECA PHARMA. Also includes updates on the valuation of ASTRAZENECA PHARMA.

More Views on News

Most Popular

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

What if Indiabulls Housing Finance and Yes Bank Do Not Rebound?(Profit Hunter)

Oct 1, 2019

How long should you wait for fallen blue chips like Yes Bank and Indiabulls Housing Finance to rebound?

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

Foreign Money is Chasing Indian Stocks Once Again(The 5 Minute Wrapup)

Oct 4, 2019

Around Rs 75 billion poured into the Indian stock market in the month of September.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

CADILA HEALTHCARE SHARE PRICE


Oct 14, 2019 01:17 PM

TRACK CADILA HEALTHCARE

  • Track your investment in CADILA HEALTHCARE with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON CADILA HEALTHCARE

CADILA HEALTHCARE 5-YR ANALYSIS

COMPARE CADILA HEALTHCARE WITH

MARKET STATS